[Form 4] Adverum Biotechnologies, Inc. Insider Trading Activity

Rhea-AI Filing Summary

The Form 4 filed on 20 Jun 2025 reveals that Adverum Biotechnologies (ADVM) director Soo Hong received a stock-option grant for 10,450 common shares on 17 Jun 2025 at an exercise price of $2.32 per share. The options vest on the earlier of 17 Jun 2026 or the company’s 2026 annual stockholder meeting, with accelerated vesting upon a change-of-control, and they expire on 16 Jun 2035.

After the grant, Hong beneficially owns 10,450 derivative securities; the filing shows no change in non-derivative share ownership, no open-market buying or selling, and no 10b5-1 trading plan. This is a routine equity award that carries no immediate cash impact for Adverum and is typical of standard director compensation programs.

Insights

Financial Analyst

TL;DR: Routine director option grant; neutral for investors.

The 10,450-share option award at $2.32 aligns the director’s incentives without altering cash flow or ownership structure today. With vesting pushed to 2026 and no accompanying share sale or purchase, the filing signals neither insider confidence nor concern. It is standard board compensation and is unlikely to influence ADVM’s valuation or trading dynamics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hong Soo

(Last) (First) (Middle)

C/O ADVERUM BIOTECHNOLOGIES, INC.

100 CARDINAL WAY

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ ADVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	06/17/2025		A		10,450		(1)	06/16/2035	Common Stock	10,450	$0	10,450	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Aneta Fergson, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Adverum (ADVM) report in the June 2025 Form 4?

Director Soo Hong received a stock-option grant for 10,450 shares on 17 Jun 2025 at a $2.32 exercise price.

When will the new ADVM director options vest?

They vest on the earlier of 17 Jun 2026 or the company’s 2026 annual stockholder meeting, with accelerated vesting if there is a change of control.

What is the expiration date of the granted options?

The options expire on 16 Jun 2035.

Did the filing disclose any open-market share purchases or sales?

No. The Form 4 only reports an equity award; there were no purchases or sales of ADVM shares.

How many derivative securities does Soo Hong own after the transaction?

Following the grant, the director beneficially owns 10,450 derivative securities and reported no non-derivative holdings.